Related Experiment Videos
Effect of aspirin on hemostasis and thrombosis
Insights
Low-dose aspirin effectively inhibits platelet function by acetylating cyclo-oxygenase, offering significant benefits in preventing thrombosis and cardiovascular events. Side effects are primarily dose-related gastrointestinal issues, with bleeding being rare in humans.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Hematology
Background:
- Aspirin's primary mechanism involves irreversible acetylation of platelet cyclo-oxygenase (COX), a key enzyme in prostaglandin synthesis.
- Low aspirin doses (40-160 mg/day) achieve >80% inhibition of platelet COX activity, with effects lasting the platelet lifespan.
- Aspirin also inhibits vascular prostacyclin (PGI2) synthesis, though this effect is transient and requires higher doses.
Purpose of the Study:
- To review the pharmacological effects of aspirin on platelet function and vascular cells.
- To evaluate the clinical efficacy and safety of various aspirin dosages in preventing thrombotic events.
- To discuss the optimal antithrombotic dosing and side effect profile of aspirin.
Main Methods:
- Review of existing literature on aspirin's mechanism of action, pharmacokinetics, and clinical trials.
- Analysis of studies investigating aspirin's effects on platelet aggregation and PGI2 synthesis.
- Examination of data from clinical studies assessing aspirin's efficacy in preventing cardiovascular and cerebrovascular events.
Main Results:
- Low-dose aspirin (100-300 mg/day) demonstrates efficacy in preventing thrombosis in specific clinical settings like bypass grafts, hemodialysis, and unstable angina.
- Higher doses (approx. 1 g/day) are effective in preventing stroke and death in patients with cerebral ischemia.
- Aspirin doses between 300-1500 mg/day show trends towards efficacy in post-myocardial infarction patients.
- Very high doses may be thrombogenic in rabbits, but this is not observed in humans at therapeutic doses.
- Gastrointestinal disturbances are the main dose-related side effects; significant bleeding is uncommon.
Conclusions:
- Aspirin is a potent antiplatelet agent with established benefits in preventing thrombotic events across various cardiovascular conditions.
- Optimal antithrombotic dosing requires further determination, but low to moderate doses show significant clinical utility.
- While generally safe, aspirin's dose-dependent gastrointestinal side effects necessitate careful consideration, especially in patients with pre-existing bleeding risks or on anticoagulation.
Abstract:
Aspirin inhibits platelet function by acetylating platelet cyclo-oxygenase. When aspirin is administered in doses as low as 40-160 mg per day, it inhibits platelet cyclo-oxygenase activity by more than 80%. The effect of aspirin on platelet function is maintained for the life-span of the platelet and there is evidence that aspirin also acetylates platelets before they are released in the circulation and while they are still within megakaryocytes. Aspirin also inhibits the synthesis of PGI2 by vascular wall cells but compared to the platelet, this vessel wall effect is relatively short-lived and requires slightly larger doses of aspirin. In vivo studies in rabbits indicate that very high doses of aspirin are thrombogenic. However, there is no evidence that aspirin is thrombogenic in man even when administered in high therapeutic doses. The optimal antithrombotic dose of aspirin has not yet been determined. Clinically, impressive results have been obtained with low doses of aspirin (ranging from 100 to 300 mg per day) in preventing aorta coronary bypass thrombosis, in patients undergoing hemodialysis, and in patients with unstable angina. Aspirin is also effective in preventing stroke and death in patients with cerebral ischemia when administered in doses of approximately 1 gram per day. There are trends suggesting that aspirin is effective when administered in doses between 300 mg per day and 1500 mg per day in patients who have survived myocardial infarction. The side-effects of aspirin are mainly gastrointestinal and are dose-related. Generalized bleeding is very uncommon and limited mainly to patients with other hemostatic abnormalities or due to the concomitant use of anticoagulant therapy.